Successful tolerance induction by allergen immunotherapy in a patient with bee venom anaphylaxis under treatment with a Janus kinase 1/2 inhibitor
Open Access
- 30 October 2025
- journal article
- Published by Elsevier in The Journal of Allergy and Clinical Immunology: In Practice
- Vol. 14 (1) , 306-308
Abstract
No abstract availableKeywords
This publication has 8 references indexed in Scilit:
- Type of vaccine and immunosuppressive therapy but not diagnosis critically influence antibody response after COVID-19 vaccination in patients with rheumatic diseaseRMD Open, 2022
- Allergen immunotherapy: past, present and futureNature Reviews Immunology, 2022
- Rheumatoid arthritis patients treated with Janus kinase inhibitors show reduced humoral immune responses following BNT162b2 vaccinationRheumatology, 2021
- Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population: a multicentre studyAnnals of the Rheumatic Diseases, 2021
- Characterization and Changes of Lymphocyte Subsets in Baricitinib‐Treated Patients With Rheumatoid ArthritisArthritis & Rheumatology, 2018
- Decline of Ves v 5-specific blocking capacity in wasp venom-allergic patients after stopping allergen immunotherapyAllergy, 2015
- Manifestation of rheumatoid arthritis during subcutaneous allergen-specific immunotherapy with bee venomJournal of Allergy and Clinical Immunology, 2012
- Birch pollen immunotherapy results in long-term loss of Bet v 1–specific TH2 responses, transient TR1 activation, and synthesis of IgE-blocking antibodiesJournal of Allergy and Clinical Immunology, 2012